LONDON, ONTARIO, Nov 12 (MARKET WIRE) --
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced
today that the Company has engaged Pullan Consulting to bolster its
internal efforts in obtaining a licensing deal for its lead oncology
compound COTI-2.
Established in 2006, Pullan Consulting is a California-based
biotechnology business development consulting firm led by Dr. Linda
Pullan, Ph.D. that has worked with over 50 biotech and pharmaceutical
companies in an advisory capacity related to drug development, valuation
analysis and negotiation for strategic alliances and licensing deals.
Dr. Pullan has more than 20 years of experience in the pharmaceutical and
biotechnology industry. Prior to establishing Pullan Consulting, Dr.
Pullan was Vice President of Business Development of Kosan Biosciences
Inc., a cancer therapeutics company acquired by Bristol-Myers Squibb in
2008, Director of Oncology and Hematology Licensing at Amgen Inc.,
Collaborations Manager at ICI/Zeneca (now AstraZeneca), and worked in
drug discovery research at Monsanto/Searle (now Pfizer). She earned her
Ph.D. in Biochemistry from the University of California at Riverside. She
has authored 66 publications. Dr. Pullan has completed 8 deals as a
consultant and more than 20 deals during her business development career
including preclinical licensing deals and company acquisitions.
"I'm delighted to be able to work with the COTI team. I have found their
approach to science and partnering both professional and thoughtful,"
said Dr. Pullan. "I am intrigued by COTI-2's novel mechanism of action,
and with efficacy shown in animals against several cancer cell lines and
low toxicity, I believe it is a highly marketable asset. I look forward
to working with COTI on a successful licensing transaction."
"We are very pleased to have engaged Pullan Consulting. This marks an
intensification in our efforts to enter into a licensing deal for our
lead oncology candidate COTI-2", said COTI Chief Executive Officer,
Michael Cloutier. "Dr. Pullan's track record of success in deal making is
very relevant not only for licensing COTI-2, but also for our growing
portfolio of drug development candidates."
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called
CHEMSAS(R), which allows for the accelerated identification, profiling
and optimization of targeted small molecules potentially effective in the
treatment of human diseases for which current therapy is either lacking
or ineffective. Currently, six targeted libraries of lead compounds are
under active development; small cell lung cancer, multiple sclerosis, HIV
integrase inhibitors, acute myelogenous leukemia, colorectal cancer and
Alzheimer's disease.
For further information, please visit the website at
www.criticaloutcome.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc. (COTI)
Michael Barr
Director of Business Development and Marketing
519-858-5157
Copyright 2009, Market Wire, All rights reserved.
-0-
